1. Introduction {#sec1-ijms-17-00833}
===============

Patent and reliable vascular access is of vital importance to end stage renal disease (ESRD) patients who receive hemodialysis \[[@B1-ijms-17-00833]\] as their choice of renal replacement therapy (RRT). Arterio-venous fistula (AVF), in comparison with arterio-venous graft (AVG) and tunneled dialysis catheter (TDC), is the best vascular access in terms of higher blood flow rate, lower infection rate, and longer lifespan \[[@B2-ijms-17-00833]\]. The thrombosis and occlusion of AVFs diminish the dialysis adequacy and increase the morbidity and mortality of HD patients \[[@B3-ijms-17-00833]\]. Neo-intimal hyperplasia (NIH) causes the maturation failure of AVF, while the recurrent thrombosis compromises the patency in the long-term. Excessive strength and duration applied on puncture site, insufficient anticoagulation use and infection of vascular access all contribute to the recurrent thrombosis of AVF. Multiple studies had been conducted to define the genetic risk factors of AVF thrombosis \[[@B3-ijms-17-00833],[@B4-ijms-17-00833],[@B5-ijms-17-00833]\]. Coagulation-related genes, hyperhomocysteinemia-related methylene tetrahydrofolate reductase (*MTHFR*) gene, transforming growth factor-b1 (*TGFB1*), matrix metalloproteinases (MMPs), hypoxia inducible factor-1α (*HIF1A*), heme oxygenase-1 (*HO1*) and vascular endothelial growth factor-A (*VEGFA*) and its receptors (*FLT1* for VEGFR-1 and *KDR* for VEGFR-2) have all been studies for their association with AVF stenosis or thrombosis.

The renin-angiotensin-aldosterone system plays an important role in the regulation of blood pressure and homeostasis of body fluid. The impact of genetic polymorphism of ACE on AVF thrombosis has been studied but contradictory results had been found \[[@B6-ijms-17-00833],[@B7-ijms-17-00833],[@B8-ijms-17-00833],[@B9-ijms-17-00833],[@B10-ijms-17-00833],[@B11-ijms-17-00833]\]. Fewer studies focused on the role of angiotensin II receptor 1/2 (AGTR1/2) in the pathogenesis of AVF thrombosis. The aim of this study was to conduct a case-control study to discover whether single nucleotide polymorphism (SNP) of renin-angiotensin-aldosterone system (RAAS) genes (including Angiotensinogen (*AGT*), Angiotensin converting enzyme gene (*ACE*), angiotensin II receptor 1 (*AGTR1*) and 2 (*AGTR2*)) could be genetic risk factors of AVF thrombosis.

2. Results {#sec2-ijms-17-00833}
==========

2.1. Patient Characteristics {#sec2dot1-ijms-17-00833}
----------------------------

Totally, 577 ESRD patients were enrolled into our study. The demographic and clinical characteristics of study subjects are shown in [Table 1](#ijms-17-00833-t001){ref-type="table"}. Among them, 154 patients had AVF malfunction and the other 423 patients were included as control group. The mean age of the AVF malfunction patients and control group patients was 60.7 ± 16.1 and 59.8 ± 14.0 years old, respectively (*p* = 0.517). There was no difference in the proportion of gender between the two groups: 55.2% of AVF malfunction patients were male and 52.2% of control group were male (*p* = 0.531). Vintage of HD was significantly longer in AVF malfunction group than in control group (92.5 ± 68.1 *versus* 61.2 ± 51.9 months, *p* \< 0.001). No significant difference between patients with and without AVF malfunction in the frequency of smoking was observed (11.7% *vs.* 9.5%, *p* = 0.432). As to the comorbidity, the prevalence of diabetes mellitus, cerebrovascular accident, peripheral arterial disease and coronary artery disease did not differ between patients with AVF malfunction and control group ([Table 1](#ijms-17-00833-t001){ref-type="table"}). However, the prevalence of hypertension in AVF malfunction group was significantly lower (44.8% *versus* 55.3%, *p* = 0.025). As to the hemodialysis-related parameters, ESRD patients with AVF malfunction had significantly higher average dynamic venous pressure (DVP) than control group (147.8 ± 28.3 *versus* 139.8 ± 30 mmHg, *p* = 0.021). However, there was no significant difference between patients with and without AVF malfunction in pre-HD mean arterial pressure (104.8 ± 17.6 *vs.* 109.7 ± 19.1 mmHg, *p* = 0.109) and post-HD mean arterial pressure (92.8 ± 14.4 *vs.* 96.6 ± 15.1 mmHg, *p* = 0.184). Delivered dialysis dosage was similar between two groups of patients, in terms of Kt/V and urea reduction rate (URR) ([Table 1](#ijms-17-00833-t001){ref-type="table"}).

SNPs of RAAS-related genes studied in our study are listed in [Table 2](#ijms-17-00833-t002){ref-type="table"}. All SNPs tested in our study were within Hardy-Weinburg equilibrium.

2.2. Univariate Analysis of the Risk Factor of AVF Malfunction {#sec2dot2-ijms-17-00833}
--------------------------------------------------------------

### 2.2.1. Clinical and Genetic Risk Factor of AVF Malfunction in all Study Subjects {#sec2dot2dot1-ijms-17-00833}

We included each clinical and demographic characteristic and genotype of each SNP for univariate analysis. Patients with two major alleles are grouped as control and patients with one or two minor alleles are grouped as risk group. Logistic regression was performed and the results are expressed as odds ratio with 95% confidence interval and p value is also listed in [Table 3](#ijms-17-00833-t003){ref-type="table"}. Right-sided AVF (Odds ratio (OR) 2.064, *p* = 0.001), upper arm location of AVF (OR 3.381, *p* \< 0.001) and increasing dynamic venous pressure (OR 1.011 for each increment of 1 mmHg, *p* \< 0.001) were statistically significant risk factors for AVF malfunction. Hypertension, in contrast, was a significant protective factor of AVF malfunction (OR 0.656, *p* = 0.026). None of the SNPs of *AGT*, *ACE*, *AGTR1* and *AGTR2* genes were identified as significant risk factor of AVF malfunction. Estrogen has been widely known to possess protective effects on cardiovascular system \[[@B12-ijms-17-00833]\], thus we divided the study subjects according to different genders for further analysis of possible clinical impact of SNPs.

### 2.2.2. Clinical and Genetic Risk Factor of AVF Malfunction in Female Study Subjects {#sec2dot2dot2-ijms-17-00833}

Upper arm location of AVF (Odds ratio (OR) 2.690, *p* = 0.004) and increasing dynamic venous pressure (OR 1.017 for each increment of 1 mmHg, *p* = 0.001) were the only two risk factors for AVF malfunction in female HD patients ([Table 4](#ijms-17-00833-t004){ref-type="table"}). Laterality of AVF was not a significant factor for AVF malfunction in female HD patients (OR 0.766, *p* = 0.411). Hypertension seemed to have protective effects on AVF, but there is no statistical significance (OR 0.606, *p* = 0.077). None of the SNPs of *AGT*, *ACE*, *AGTR1* and *AGTR2* genes is identified as significant risk factor of AVF malfunction in female HD patients.

### 2.2.3. Clinical and Genetic Risk Factor of AVF Malfunction in Male Study Subjects {#sec2dot2dot3-ijms-17-00833}

Among male HD patients in current study, right-sided AVF (OR 3.051, *p* \< 0.001) and upper arm location of AVF (OR 4.474, *p* \< 0.001) were two risk factors for AVF malfunction. Protective effect of HTN was not observed in male subgroup. Increasing dynamic venous pressure seemed to increase the risk of AVF malfunction, with borderline statistical significance (OR 1.008 for each increment of 1 mmHg, *p* = 0.061). Two SNPs in *AGTR1* gene probably had adverse impacts on AVF patency. The first one is rs275653 (Promotor (g. −113), −153A\>G) and male HD patients with minor allele (AG or GG) had higher risk of AVF malfunction than those with major alleles only (GG genotype) (OR 1.900, *p* = 0.038). Another potential genetic risk factor of AVF malfunction is rs1492099 (Intron (IVS2 + 11689)). Male HD patients having minor allele (CA or AA genotype) were associated with higher prevalence of AVF malfunction than those carrying two major alleles (CC genotype) ([Table 5](#ijms-17-00833-t005){ref-type="table"}). None of SNPs in *AGT* gene, *ACE* gene or *AGTR2* gene was significantly associated with AVF malfunction. However, AG or GG genotype of rs6687360 (Intron(IVS2+749)) of *AGT* gene and TC or CC genotype of rs5182 (Synonymous coding(Exon3, c. +573)) had potential effects on AVF patency; thus, these two SNPs were also included in the following multivariate analysis (OR 1.615, *p* = 0.076 and OR 1.623, *p* = 0.084, respectively, [Table 5](#ijms-17-00833-t005){ref-type="table"}).

2.3. Multivariate Analysis of Risk Factors of AVF Malfunction in Male HD Patients {#sec2dot3-ijms-17-00833}
---------------------------------------------------------------------------------

To define the risk factor of AVF malfunction in male HD patients, we included clinical and genetic parameters with stronger association with AVF malfunction, *i.e.*, *p* \< 0.200 in univarate binary logistic regression, and perform multivariate Cox-regression analysis. Forward likelihood ratio test was applied to construct the model. Age, hypertension, laterality of AVF, upper arm/forearm location of AVF, dynamic venous pressure, rs275653, rs1492099, rs6687360, rs5182 and rs409742 are included into analysis. As shown in [Table 6](#ijms-17-00833-t006){ref-type="table"}, right-sided AVF (OR 3.611, *p* = 0.001), upper arm location of AVF (OR 3.384, *p* = 0.003) and CA or AA genotype of rs1492099 (OR 3.355, *p* = 0.008) remain significantly associated with AVF malfunction after adjustment.

3. Discussion {#sec3-ijms-17-00833}
=============

3.1. AVF Malfunction, HD Characteristics and Comorbidities {#sec3dot1-ijms-17-00833}
----------------------------------------------------------

The longer duration of hemodialysis represents much more total needle puncture times. Repeated injury to AVF may induce local inflammation, thrombosis and fibrotic change or stenosis. In our study, hemodialysis patients with AVF malfunction have significantly longer HD duration than control group. The finding is compatible with aforementioned pathophysiology of development of AVF malfunction. In our study population, most of the patients, like other cultural groups in the world, are right-handed.

Cardiovascular surgeons tend to establish AVF anastomosis on the forearm of non-dominant upper extremity, *i.e.*, left forearm. HD patients who had their AVF on dominant side and upper arm might have worse vascular condition \[[@B13-ijms-17-00833]\].

In our study, HD patients without AVF malfunction have significantly higher prevalence of HTN ([Table 1](#ijms-17-00833-t001){ref-type="table"}). Hypertension is also found to be a protective factor for AVF malfunction in univariate analysis of all study subjects ([Table 3](#ijms-17-00833-t003){ref-type="table"}). Hemodialysis patients with lower blood pressure may be prone to develop intradialytic hypotension, lower blood flow rate and thus may result in clotting within dialyzer or vascular access. Therefore, HD patients who have HTN may probably benefit from a higher blood pressure, whether during or between hemodialysis sessions. However, protective effects of HTN are not significant among male HD patients. One possible explanation is that the male patients tended to exercise their upper limbs more often, whether in their labor work or recreational activities. Larger muscle girdle may potentially interfere with the measurements of blood pressure.

Compared with HD patients without AVF malfunction, HD patients with AVF malfunction have higher average dynamic venous pressure ([Table 1](#ijms-17-00833-t001){ref-type="table"}). Higher dynamic venous pressure implicates hindrance of venous return, such as thrombosis or stenosis. Thrombosis and stenosis are both the major mechanical causes of AVF malfunction.

3.2. Genetic Risk Factors of AVF Malfunction {#sec3dot2-ijms-17-00833}
--------------------------------------------

Various studies have been conducted to delineate the association between genetic polymorphisms and arteriovenous fistula patency. In our previous study, length polymorphism of dinucleotide guanosine thymine repeat (GT)*n* in the promoter region of heme oxygenase-1 (*HO1*) was found to be associated with AVF patency. Longer GT repeat in promoter region of *HO1* may hinder the transcription of the gene, and eventually attenuate the protective effect of heme oxygenase-1 on AVF \[[@B5-ijms-17-00833]\]. Recent publication from our group also discovered that SNP of protein arginine methyltransferase 1 (*PRMT1*) gene has statistically significant association with primary patency, assisted primary patency and secondary patency of AVF in male HD patients \[[@B14-ijms-17-00833]\].

Clinical implication of genetic polymorphism of *ACE* gene, especially *ACE* insertion/deletion (*ACE* I/D), has been extensively studied \[[@B6-ijms-17-00833],[@B7-ijms-17-00833],[@B8-ijms-17-00833],[@B9-ijms-17-00833],[@B10-ijms-17-00833],[@B11-ijms-17-00833]\]. On microvascular scale, Hadjadj *et al.* \[[@B9-ijms-17-00833]\] conducted a large, family-based, case-control study in 3 different European populations and they discovered that five *ACE* polymorphisms (rs1800764-C, rs4311-T, Insertion/deletion (I/D or rs1799752)-D, rs4366-G, and rs12449782-G alleles) had statistically significant association with increased risk of diabetic nephropathy. However, contradictory results were shown by different studies and ethnic group and gender may contribute to the disparities of results. In a Taiwanese study completed by Tien *et al.* \[[@B15-ijms-17-00833]\], female diabetic patients with *ACE* ID or DD genotype were associated with higher risk of diabetic nephropathy than those with *ACE* II genotype. On macrovascular scale, *ACE* polymorphisms have been found to be associated with cerebrovascular accident \[[@B16-ijms-17-00833]\]. However, a recent Spanish case-control study by Domingues-Montanari *et al.* demonstrated that there was no significant association between *ACE* polymorphism and ischemic stroke, despite elevated serum level of ACE in *ACE* DD genotype group \[[@B11-ijms-17-00833]\]. In our study, none of the selected SNPs of *ACE* gene was associated with AVF malfunction, which was compatible with previous studies \[[@B3-ijms-17-00833],[@B6-ijms-17-00833]\]. In a longitudinal study conducted by Heine *et al.*, 137 HD patients with AVF were enrolled and AVF patency 12 months after creation of AVF were not significantly different among patients with different genotypes (*ACE* II, ID and DD). Effects of angiotensin converting enzyme inhibitor (ACE-I) and angiotensin receptor blocker (ARB) were evaluated and the results showed ACE-I/ARB had no positive effects on AVF patency \[[@B6-ijms-17-00833]\]. However, a Korean study with similar scale but longer follow-up period had the opposite discoveries \[[@B17-ijms-17-00833]\]. Recently, another smaller study revealed possible association between *ACE* DD genotype and higher risk of early thrombosis of AVF in HD patients, in comparison with HD patients with *ACE* II or ID genotype \[[@B7-ijms-17-00833]\].

Genetic polymorphisms of *AGTR1* have been found to be closely related to cardiovascular diseases, metabolic disorders and even longevity in previous studies \[[@B18-ijms-17-00833],[@B19-ijms-17-00833],[@B20-ijms-17-00833],[@B21-ijms-17-00833],[@B22-ijms-17-00833]\]. The most widely studied SNP of *AGTR1* gene, rs5182 (A1166C) is located on the 3′-UTR of AGTR1 gene exon 3. Recently, a meta-analysis by Liu *et al.* included 56 studies and 28,952 study subjects and the study found that *AGTR1* A1166C was associated with higher risk of hypertension, whether in Asian or Caucasian populations \[[@B23-ijms-17-00833]\]. Significant association between *AGTR1* rs5182 and hypertension was also found in Mexican population \[[@B19-ijms-17-00833]\]. Interestingly, previous epidemiology-genomic studies have found the patients with *AGTR1* CC genotype were at increased risk of in stent restenosis (ISR) after percutaneous coronary intervention, whether in Caucasian or Asian ethnic groups \[[@B24-ijms-17-00833],[@B25-ijms-17-00833]\]. However, in our study, there was no statistically significant association between rs5182 and AVF malfunction ([Table 3](#ijms-17-00833-t003){ref-type="table"}, [Table 4](#ijms-17-00833-t004){ref-type="table"} and [Table 5](#ijms-17-00833-t005){ref-type="table"}). Even it is included into multivariate analysis of male HD patients, it did not appear to be a significant risk factor of AVF malfunction ([Table 6](#ijms-17-00833-t006){ref-type="table"}). In our study, another 2 SNPs of *AGTR1* gene were found to be associated with AVF malfunction: rs275653 and rs1492099. *AGTR1* rs275653 was included by the gene association study in Mexican population, it turned out that rs275653 was not associated with hypertension \[[@B19-ijms-17-00833]\]. In a gene association study involving Italian centenarian cohort and Japan validation centenarian cohort, rs275653 C-G-C genotype (minor allele) has been found to be associated with longevity, less AGTR1-expressing peripheral blood neutrophils and lower blood pressure \[[@B20-ijms-17-00833]\]. In our study, patients with minor allele of rs275653 were at increased risk of AVF malfunction, probably due to lower blood pressure. *AGTR1* rs1492099 was the other significant risk factor for AVF malfunction. Unfortunately, limited literature revealed the clinical implication of this SNP. Sotoodehnia *et al.* have conducted a case-control study on adverse cardiovascular effects of SNPs of angiotensin-converting enzyme-related genes \[[@B18-ijms-17-00833]\]. In this study, minor allele of rs1492099 had significant association with decreased risk of sudden cardiac death (OR 0.62, 95% CI 0.4--0.9). In our study, male HD patient with rs1492099 minor allele were at increased risk of AVF malfunction ([Table 5](#ijms-17-00833-t005){ref-type="table"} and [Table 6](#ijms-17-00833-t006){ref-type="table"}). The proportion of AVF malfunction in all male HD patients was 26.7%; however, the proportion of AVF malfunction in male HD patients with minor allele of *AGTR1* rs1492099 was 43.9%. Although *AGTR1* rs1492099 locates on intron of *AGTR1* gene, it could possess regulatory effects on transcription of *AGTR1*, which may cause increased/decreased expression. Altered expression of *AGTR1* may cause decreased systemic expression, which may result in lower prevalence of hypertension. In contrast, minor allele of rs1492099 may result in increased expression of *AGTR1*, which renders HD patients become more susceptible to angiotensin II, augmented vascular smooth muscle cell proliferation, neointimal hyperplasia and eventually stenosis and malfunction of AVF \[[@B26-ijms-17-00833],[@B27-ijms-17-00833],[@B28-ijms-17-00833]\]. ACE-I or ARB may be the "double-blade sword." One possible therapeutic approach is that ACE-I/ARB should be considered as the "first" antihypertensive in HD patients with hypertension, to gain their beneficial effects on inhibition of vascular smooth muscle cell proliferation, meanwhile, to avoid hypotension episodes that may increase the risk of AVF malfunction or thrombosis.

Adverse effects of *AGTR1* SNPs were observed only in male HD patients but not in female HD patients. An animal study of estrogen effects on adrenal gland secretion showed that estrogen repressed the expression of AGTR1 and obtunded the aldosterone release stimulated by angiotensin II \[[@B29-ijms-17-00833]\]. Generally speaking, estrogen may lower the AT1 receptor density and increased AT2 receptor density \[[@B30-ijms-17-00833]\]. Therefore, it is possible that the up-regulation effect of SNPs on AGTR1 are attenuated or "overwritten" by hormone effects in female patients.

3.3. Limitations {#sec3dot3-ijms-17-00833}
----------------

There are several limitations in our study: First, lack of time dependent variable, such as the prospective follow-up period, makes analysis of causal relationship between clinical/genetic factors and AVF malfunction inapplicable. HD vintage in patients without AVF malfunction is significantly shorter. The actual prevalence of AVF malfunction among control patients when their HD vintage reaches to similar duration as AVF malfunction group is unknown. Second, robust statistical analysis cannot be performed due to relatively small numbers of study subjects. Third, all the study subjects are Taiwanese and the results in our study may not be extrapolated to other ethnic groups. A similar cohort with detailed SNP data in Taiwan may be used to validate our findings, unfortunately, there was no such independent cohort in previously published studies. Fourth, although we advocated the estrogen effect as an interpretation of gender differences on effects of SNPs, further subgroup analysis of premenopausal and menopausal female patients was not available because of limited patient number in our study. Fifth, selection bias may exist in the cross-sectional study design *per se*. Sixth, detailed information on medication use of ACE-I or ARB is not available, thus it is difficult to delineate the true clinical effects of angiotensin or angiotensin receptor. Last, but not least important, no blood chemistry data were available to calculate Kt/V or urea reduction rate and no CRP (C-reactive protein) or albumin level data were available to determine the status of inflammation or malnutrition, respectively.

4. Materials and Methods {#sec4-ijms-17-00833}
========================

4.1. Study Subjects {#sec4dot1-ijms-17-00833}
-------------------

All ESRD patients receiving regular HD therapy at eight different medical institutions during January to March 2008 were screened for eligibility of current study. The eight medical institutions included five local hemodialysis centers, two regional hospitals and one medical center. The inclusion criteria were listed as follows: adult age elder than 18 years old, prevalent ESRD patients who received stable HD (HD therapy for more than 3 months), using native AVF at upper extremities. Definition of AVF malfunction in current study is the loss of functional patency (patent AVF which can tolerate extracorporeal blood flow more than 200 mL/min during dialysis), any angioplasty or surgery to re-establish AVF patency and total occlusion of the AVF. To investigate specifically on AVF thrombosis, patients with AVF malfunction which were attributed to complications other than thrombosis are excluded, *i.e.*, patients with vascular access infection, aneurysm formation with or without surgical ligation, and dialysis access-associated steal syndrome. Patients with AVF maturation failure (AVF malfunction within 3 months after surgery) were also excluded. Informed consent was obtained from each participant of the study; clinical information and blood sample were then collected. We recorded demographic and clinical information of all the patients recruited, including age, gender, HD vintage, location (upper arm or forearm) and laterality (right or left) of the AVF. Underlying comorbidities such as hypertension (HTN), diabetes mellitus \[[@B31-ijms-17-00833]\], peripheral arterial occlusive disease (PAOD), cerebrovascular disease (CVA), coronary artery disease (CAD) were all recorded. Hemodialysis-related parameters including maximal blood flow rate during HD and dynamic venous return pressure (DVP) were also documented. The conduction of the study was under the surveillance of the Institutional Research Board of Taipei Veterans General Hospital.

4.2. DNA Isolation and Genotyping of Renin-Angiotensin-Aldosterone System-Related Genes {#sec4dot2-ijms-17-00833}
---------------------------------------------------------------------------------------

Venous blood samples with anticoagulant were collected from all study subjects and isolation of genomic DNA was done by using Puregene DNA purification kit (Gentra, Minneapolis, MN, USA). Fifty to 100 ng of DNA was amplified into a final volume of 10 μL, which contained 0.5 U HotStar Taqpolymerase (Qiagen, Hilden, Germany), 1× solution Q (Qiagen), 10× reaction buffer (Qiagen), MgCl~2~ (Qiagen), 200 μmol each deoxynucleoside triphosphate (Roche Applied Science, Mannheim, Germany) and 10 μmol of each primer. The protocol of thermal cycler for DNA amplification was the following: 95 °C for 12 min, 30 cycles of 95 °C for 1 min, 60 °C for 30 s, 72 °C for 1 min, 72 °C for 8 min. Electrophoresis with 2% agarose gel was used for fractionation of amplified DNA products. The DNA bands in each lane were visualized by ultraviolet light and ethidium bromide staining (0.5 mg/mL). [Table 1](#ijms-17-00833-t001){ref-type="table"} listed the primer sequences of selected SNP in current study. Direct sequencing (allelic discrimination with TaqMan MGB probe by ABI 7700) and restriction fragment length polymorphism (RFLP) were applied to determine the SNP genotyping. Positive and negative controls were included in all typing analysis.

4.3. Statistical Analysis {#sec4dot3-ijms-17-00833}
-------------------------

We checked Hardy--Weinberg equilibrium for the genotype polymorphisms \[[@B32-ijms-17-00833]\]. Continuous variables were expressed as mean ± SD and Student's *t*-test was used to compare differences between groups. Categorical variables were depicted as median with interquartile range and we applied χ-square test to determine differences between groups. Logistic regression was used to define whether each clinical factor or SNP could be the risk factor for AVF malfunction. Multivariate logistic regression model was used for adjustment of confounders and determination of independent risk factors of AVF thrombosis. We performed two-sided tests in statistical analysis and *p* value less than 0.05 was considered to imply statistical significance. Statistical Package for the Social Sciences (SPSS) version 18.0 (SPSS, Chicago, IL, USA) was applied in statistical analysis.

5. Conclusions {#sec5-ijms-17-00833}
==============

In the current study, rs1492099, a SNP of *AGTR1* gene, is an independent risk factor for AVF malfunction, even after adjustment of other candidate SNPs and clinical factors. Further well-designed study with larger scale or related animal study is needed to determine the exact effects of this SNP.
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ijms-17-00833-t001_Table 1

###### 

Clinical characteristics of Hemodialysis (HD) patients by status of Arterio-venous fistula (AVF) malfunction.

  Characteristic                                                 Malfunction (*n* = 154)   No Malfunction (*n* = 423)   *p* Value
  -------------------------------------------------------------- ------------------------- ---------------------------- -----------
  Age (years)                                                    60.7 ± 16.1               59.8 ± 14.0                  0.517
  Gender (%)                                                                                                            
  Male                                                           55.2                      52.2                         0.531
  Female                                                         44.8                      47.8                         
  HD duration (months)                                           92.5 ± 68.1               61.2 ± 51.9                  \<0.001
  Smoking (%)                                                    11.7                      9.5%                         0.432
  Hypertension (%)                                               44.8                      55.3                         0.025
  Diabetes mellitus (%)                                          26.1                      31.9                         0.173
  Cerebrovascular accidents (%)                                  11.0                      7.3                          0.192
  Peripheral arterial disease (%)                                5.2                       4.0                          0.540
  Coronary artery disease (%)                                    23.0                      20.2                         0.462
  ACE inhibitor (%)                                              9.7                       11.1                         0.643
  ARB (angiotensin II receptor blocker) (%)                      14.9                      18.0                         0.391
  Site of AVF (%)                                                                                                       
  Right side                                                     31.8                      18.4                         0.002
  Left side                                                      68.2                      81.6                         
  Location of AVF (%)                                                                                                   
  Forearm                                                        73.4                      90.3                         \<0.001
  Upper arm                                                      26.6                      9.7                          
  Dynamic venous pressure (mmHg) under pump flow at 250 mL/min   147.8 ± 28.3              139.8 ± 30.0                 0.021
  Pre-dialytic mean arterial blood pressure (mmHg)               104.8 ± 17.6              109.7 ± 19.1                 0.109
  Post-dialytic mean arterial blood pressure (mmHg)              92.8 ± 14.4               96.6 ± 15.1                  0.184
  KT/V                                                           1.38 ± 0.13               1.49 ± 0.15                  0.113
  URR (urea reduction rate) (%)                                  73 ± 4.9                  76 ± 5.2                     0.124
  Maximal pump flow (mL/min)                                     268.6 ± 29.3              274.5 ± 36.3                 0.106

HD, hemodialysis; AVF, arteriovenous fistula.

ijms-17-00833-t002_Table 2

###### 

Primer sequences and PCR conditions for amplification of polymorphisms within renin-angiotensin-aldosterone system-related genes.

  Gene                                             SNP Name Position                             Chromosome Position             Genotyping Method               Primer                            Sequence (5′ to 3′)         Allele \*
  ------------------------------------------------ --------------------------------------------- ------------------------------- ------------------------------- --------------------------------- --------------------------- -----------
  *AGT*                                            rs7079 exon5 (c. +1866)                       chr1:230838331                  TaqMan Allelic discrimination   Forward                           TGAAAGATGCAAGCACCTGAA       C/A \*
  Reverse                                          TTGGAGGCTTATTGTGGCAAG                                                                                                                                                       
  rs11568056 Intron (IVS2-551)                     chr1:230842497                                RFLP-PCR                        Forward                         GACAGCTGGTGGGCTCTG                G/A \*                      
  Reverse                                          (6Fam)-CAAAGGCTGTGGTTTGACAC                                                                                                                                                 
  rs6687360 Intron (IVS2+749)                      chr1:230844992                                RFLP-PCR                        Forward                         (6Fam)-GTGCCATCATTGCTCACTGT       T/C \*                      
  Reverse                                          GGCCTATACAGCCCTCCTCT                                                                                                                                                        
  rs4762 Non-synonymous 207 T\>M Exon2, c. +620    chr1:230845977                                RFLP-PCR                        Forward                         (6Fam)-CTACAGGCAATCCTGGGTGT       C/T \*                      
  Reverse                                          AGGCCTGACTGGCTGATCT                                                                                                                                                         
  rs11568028 Intron (IVS1-645)                     chr1:230847244                                RFLP-PCR                        Forward                         (6Fam)-GGACCACAGGGAGATGACAA       G/A \*                      
  Reverse                                          ATGAGGCCATGAGGGTGA                                                                                                                                                          
  rs3789678 Intron (IVS1+350)                      chr1:230849482                                RFLP-PCR                        Forward                         GGACAAGATGGTCAGGTCTTC             C/T \*                      
  Reverse                                          (6Fam)-TCCCAAAGCTTAGAAAGCACT                                                                                                                                                
  rs5051 5′-UTR (Exon 1, g. +172, c. −41) -6A\>G   chr1:230849872                                RFLP-PCR                        Forward                         GTCCTTCTGGCCAGCCTGT               T/C \*                      
  Reverse                                          (6Fam)-CGGCCTTTTCCTCCTAGC                                                                                                                                                   
  *ACE*                                            rs4295 Intron (IVS2-70)                       chr17:61556298                  RFLP-PCR                        Forward                           (6Fam)-CTGTCCCCCACTCCACAG   C/G \*
  Reverse                                          GACCCTACACAACTGCATGG                                                                                                                                                        
  rs4340 Intron (Intron 16)                        chr17:61565893                                Fragment length analysis        Forward                         (6Fam)-GTAAGCCACTGCTGGAGAGC       I/D \*                      
  Reverse                                          CCAGCCCTTAGCTCACCTCT                                                                                                                                                        
  rs10853044 3′-UTR (Exon17, c. +5150)             chr17:61586549                                RFLP-PCR                        Forward                         TGGCTAAAGGGTGAGATGGTG             T/C \*                      
  Reverse                                          (6Fam)-CAGGGACAGACAGGCCAAG                                                                                                                                                  
  *AGTR1*                                          rs409742 Upstream (g. −3294)                  chr3:148412365                  RFLP-PCR                        Forward                           TTCCCACCAACAATATATGAGG      T/C \*
  Reverse                                          (6Fam)-AAACGTAGGAGTAAACCTTTGTTACC                                                                                                                                           
  rs275653 Promotor (g. −113) −153A\>G             chr3:148415545                                TaqMan Allelic discrimination   Forward                         TGAACGCTGATCTGATAGTTGACA          A/G \*                      
  Reverse                                          ACGAGGCTCTGTTTTGCATTC                                                                                                                                                       
  rs10935724 Intron (IVS1-4477)                    chr3:148421253                                RFLP-PCR                        Forward                         CATTTTAGCAAAATCCTCAGGTG           A/C \*                      
  Reverse                                          (6Fam)-CAGCTTTTGGGTAAACTACTTATCTC                                                                                                                                           
  rs1492099 Intron (IVS2+11689)                    chr3:148437503                                RFLP-PCR                        Forward                         (6Fam)-GCCTGTGCTGTTCTCAGGTT       G/A \*                      
  Reverse                                          AACTTTAAATGTTTTACAGATCCAAAT                                                                                                                                                 
  rs385338 Intron (IVS2-9620)                      chr3:148449156                                RFLP-PCR                        Forward                         (6Fam)-TTTCTTTTGGACAGCACTGAA      C/G \*                      
  Reverse                                          AATGCAAGGGTAAGTAAAATGAA                                                                                                                                                     
  rs5182 Synonymous coding (Exon3, c. +573)        chr3:148459395                                RFLP-PCR                        Forward                         (6Fam)-CATCATCATTTGGCTGCTG        T/C \*                      
  Reverse                                          CGTGTCCACAATATCTGCAA                                                                                                                                                        
  rs5186 3′-UTR (Exon3, c. 1166) 1166A\>C          chr3:148459988                                RFLP-PCR                        Forward                         GAGAACATTCCTCTGCAGCAC             A/C \*                      
  Reverse                                          (6Fam)-GAGCAGCCGTCATCTGTCTA                                                                                                                                                 
  *AGTR2*                                          rs1403543 Intron (IVS1-29, g. 218) 1675A\>G   chrX:115302192                  TaqMan Allelic discrimination   Forward                           GCAGCCTGAATTTTGAAGGT        A/G \*
  Reverse                                          TCCACTTGAAGACTTACTGGTTGT                                                                                                                                                    
  rs11091046 3′-UTR (Exon 3, c. +1593) 3123A\>C    chrX:115305126                                RFLP-PCR                        Forward                         (6Fam)-CATTGCATCATTTACAAGACAACA   C/A \*                      
  Reverse                                          ACTGTAAAAATAAGCTAAAGCATAGGA                                                                                                                                                 
  rs12840631 Downstream (g. +4317)                 chrX:115306351                                TaqMan Allelic discrimination   Forward                         TGTATCCTCCATTTTATCTCCACTGA        C/G \*                      
  Reverse                                          AGCTAATGGGAAATTATGGCTCAA                                                                                                                                                    

\* Minor allele, also as risk allele in statistical analysis.
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###### 

Univariate logistic regression model of factors associated with AVF malfunction in all HD patients.

  Clinical or Genetic Factors      Odds Ratio   95% CI Lower   95% CI Upper   Significance
  -------------------------------- ------------ -------------- -------------- --------------
  Age (year)                       1.005        0.992          1.018          0.488
  Right side *vs.* left side       2.064        1.358          3.138          0.001 \*
  Upper arm *vs.* forearm          3.381        2.090          5.469          \<0.001 \*
  Hypertension                     0.656        0.452          0.950          0.026 \*
  Diabetes mellitus                0.755        0.499          1.143          0.184
  Coronary artery disease          1.183        0.757          1.848          0.462
  Peripheral artery disease        1.309        0.553          3.097          0.541
  Cerebrovascular accident         1.569        0.842          2.925          0.156
  Dynamic venous pressure (mmHg)   1.011        1.005          1.018          \<0.001 \*
  *AGT*                                                                       
  rs7079                           1.781        0.623          5.093          0.282
  rs11568056                       1.003        0.649          1.548          0.990
  rs6687360                        1.205        0.824          1.761          0.336
  rs4762                           0.660        0.398          1.092          0.106
  rs11568028                       0.854        0.570          1.278          0.442
  rs3789678                        1.012        0.638          1.605          0.960
  rs5051                           0.922        0.609          1.398          0.703
  *ACE*                                                                       
  rs4295                           1.303        0.833          2.036          0.246
  rs4340                           1.369        0.937          2.001          0.105
  rs10853044                       1.138        0.690          1.876          0.612
  *AGTR1*                                                                     
  rs409742                         1.233        0.727          2.093          0.437
  rs275653                         1.393        0.881          2.203          0.157
  rs10935724                       0.902        0.596          1.366          0.626
  rs1492099                        1.437        0.846          2.441          0.180
  rs385338                         1.119        0.743          1.686          0.591
  rs5182                           1.285        0.852          1.937          0.231
  rs5186                           0.729        0.374          1.421          0.353
  *AGTR2*                                                                     
  rs1403543                        1.014        0.699          1.472          0.940
  rs11091046                       0.970        0.652          1.444          0.882
  rs12840631                       1.105        0.726          1.684          0.641

*AGT*, Angiotensinogen; *ACE*, Angiotensinogen-converting enzyme; *AGTR1*, Angiotensin II receptor, type 1; *AGTR2*, Angiotensin II receptor, type 2; \* *p* \< 0.05.
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###### 

Univariate logistic regression model of factors associated with AVF malfunction in female HD patients.

  Clinical or Genetic Factors      Odds Ratio   95% CI Lower   95% CI Upper   Significance
  -------------------------------- ------------ -------------- -------------- --------------
  Age (year)                       0.991        0.972          1.011          0.386
  Right side *vs.* left side       0.766        0.406          1.445          0.411
  Upper arm *vs.* forearm          2.690        1.371          5.279          0.004 \*
  Hypertension                     0.606        0.348          1.055          0.077
  Diabetes mellitus                0.664        0.342          1.287          0.225
  Coronary artery disease          0.933        0.455          1.912          0.850
  Peripheral artery disease        0.832        0.169          4.101          0.821
  Cerebrovascular accident         1.500        0.494          4.552          0.474
  Dynamic venous pressure (mmHg)   1.017        1.007          1.027          0.001 \*
  *AGT*                                                                       
  rs7079                           0.981        0.523          1.840          0.952
  rs11568056                       0.835        0.429          1.625          0.595
  rs6687360                        0.867        0.499          1.509          0.615
  rs4762                           0.510        0.234          1.110          0.090
  rs11568028                       0.766        0.413          1.423          0.399
  rs3789678                        1.310        0.662          2.590          0.438
  rs5051                           1.011        0.560          1.825          0.972
  *ACE*                                                                       
  rs4295                           1.095        0.558          2.150          0.792
  rs4340                           1.401        0.805          2.439          0.233
  rs10853044                       1.520        0.723          3.197          0.269
  *AGTR1*                                                                     
  rs409742                         0.856        0.366          2.003          0.720
  rs275653                         0.933        0.455          1.912          0.850
  rs10935724                       1.104        0.584          2.087          0.761
  rs1492099                        0.680        0.267          1.735          0.420
  rs385338                         1.204        0.669          2.167          0.535
  rs5182                           0.952        0.510          1.777          0.878
  rs5186                           0.483        0.179          1.304          0.151
  *AGTR2*                                                                     
  rs1403543                        0.982        0.546          1.768          0.953
  rs11091046                       0.871        0.474          1.600          0.656
  rs12840631                       1.136        0.641          2.013          0.661

*AGT*, Angiotensinogen; *ACE*, Angiotensinogen-converting enzyme; *AGTR1*, Angiotensin II receptor, type 1; *AGTR2*, Angiotensin II receptor, type 2; \* *p* \< 0.05.
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###### 

Univariate logistic regression model of factors associated with AVF malfunction in male HD patients.

  Clinical or Genetic Factors      Odds Ratio   95% CI Lower   95% CI Upper   Significance
  -------------------------------- ------------ -------------- -------------- --------------
  Age (year)                       1.014        0.997          1.031          0.115
  Right side *vs.* left side       3.051        1.724          5.397          \<0.0001 \*
  Upper arm *vs.* forearm          4.474        2.215          9.038          \<0.0001 \*
  Hypertension                     1.450        0.878          2.396          0.147
  Diabetes mellitus                0.806        0.470          1.380          0.432
  Coronary artery disease          1.374        0.771          2.447          0.281
  Peripheral artery disease        1.603        0.564          4.555          0.376
  Cerebrovascular accident         1.566        0.733          3.342          0.247
  Dynamic venous pressure (mmHg)   1.008        1.000          1.017          0.061
  *AGT*                                                                       
  rs7079                           0.984        0.547          1.768          0.956
  rs11568056                       1.185        0.668          2.107          0.563
  rs6687360                        1.615        0.951          2.744          0.076
  rs4762                           0.817        0.418          1.594          0.552
  rs11568028                       0.942        0.552          1.608          0.827
  rs3789678                        0.809        0.431          1.515          0.507
  rs5051                           0.850        0.472          1.530          0.588
  *ACE*                                                                       
  rs4295                           1.459        0.799          2.663          0.219
  rs4340                           1.320        0.780          2.233          0.301
  rs10853044                       0.902        0.456          1.785          0.768
  *AGTR1*                                                                     
  rs409742                         1.584        0.795          3.156          0.191
  rs275653                         1.900        1.035          3.489          0.038 \*
  rs10935724                       0.785        0.452          1.361          0.388
  rs1492099                        2.287        1.160          4.509          0.017 \*
  rs385338                         1.053        0.592          1.872          0.860
  rs5182                           1.623        0.938          2.808          0.084
  rs5186                           1.159        0.459          2.926          0.735
  *AGTR2*                                                                     
  rs1403543                        1.099        0.661          1.826          0.717
  rs11091046                       1.133        0.654          1.964          0.656
  rs12840631                       1.145        0.598          2.191          0.683

*AGT*, Angiotensinogen; *ACE*, Angiotensinogen-converting enzyme; *AGTR1*, Angiotensin II receptor, type 1; *AGTR2*, Angiotensin II receptor, type 2; \* *p* \< 0.05.
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###### 

Multivariate logistic regression model of factors associated with AVF malfunction in male HD patients.

  Clinical or Genetic Factors        Significance   Odds Ratio   95% CI Lower   95% CI Upper
  ---------------------------------- -------------- ------------ -------------- --------------
  Right side *vs.* left side         0.001 \*       3.559        1.709          7.412
  Upper arm *vs.* forearm            0.003 \*       3.837        1.590          9.258
  *AGTR1* rs1492099_CA+AA *vs.* CC   0.005 \*       3.632        1.469          8.982
  Age                                0.543          1.007        0.985          1.029
  Hypertension                       0.313          0.702        0.353          1.395
  Dynamic venous pressure            0.473          1.004        0.994          1.014
  AGT rs6687360                      0.065          1.885        0.962          3.692
  AGTR1 rs409742                     0.522          1.500        0.433          5.195
  AGTR1 rs275653                     0.913          0.917        0.195          4.307
  AGTR1 rs5182                       0.712          1.148        0.551          2.391

*AGT*, Angiotensinogen; *ACE*, Angiotensinogen-converting enzyme; *AGTR1*, Angiotensin II receptor, type 1; *AGTR2*, Angiotensin II receptor, type 2 \* *p* \< 0.05.
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